https://www.selleckchem.com/pr....oducts/vx803-m4344.h
asymmetry as a biomarker for disease progression.Introduction Despite surgical and chemotherapeutical treatment options, the prognosis for glioblastoma (GBM) remains poor. Some studies have found that using lomustine plus bevacizumab to treat GBM can prolong overall survival (OS) and progression-free survival (PFS). The aim of this study was to explore the efficacy of the two drugs in combination treatment of GBM using a meta-analysis of the existing literature to help settle the ongoing debate. Materials and Methods PubMed, EMBASE,
Aimer
Commentaire
Partagez
